When was Proxima founded?

Proxima was founded in 2019 and raised its 1st funding round 7 years after it was founded.

Where is Proxima located?

Proxima is headquartered in New York City, United States.

Who is the current CEO of Proxima?

Zachary Carpenter of Proxima. They have also founded 1 company.

How many employees does Proxima have?

As of Sep 30, 2026, the latest employee count at Proxima is 75.

Is Proxima a funded company?

Proxima is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 12, 2026.

When was the latest funding round of Proxima?

Proxima's latest funding was a $***** Seed round on Jan 12, 2026, with participation from 9 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $3.89B in funding in 2026 to date.

Where does Proxima rank among its competitors?

Proxima ranks 18th amongst 70 active competitors, of which 40 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Converge, which secured $2.5M in Jun, 2026.

Who are the top competitors of Proxima?

Proxima's top competitors include Cradle, Generate Biomedicines and Profluent Bio. Among them, Converge secured the most recent funding round in June, 2026.

Proxima - 2026 Company Profile, Team, Funding & Competitors

Proxima is a seed company based in New York City (United States), founded in 2019 by Zachary Carpenter. It operates as a Developer of a platform for programmable protein interaction-based drug discovery. Proxima has raised $86.3M in funding from DCVC. The company has 70 active competitors, including 40 funded and 4 that have exited. Its top competitors include companies like Cradle, Generate Biomedicines and Profluent Bio.

Company Details

Developer of a platform for programmable protein interaction-based drug discovery. The company offers technologies to discover proximity modulators, including inducers, modulators, and blockers. It focuses on advancing artificial intelligence drug discovery through data generation.

Website: proximabio.com
Social
Email ID: *****@proximabio.com

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Seed

Total Funding

$86.3M in 1 round

Latest Funding Round

Seed, Jan 12, 2026, $*****

Investors

DCVC & 8 more

Ranked

18^th among 70 active competitors

Employee Count

75 as on Sep 30, 2026

Similar Companies

Cradle & 74 more

View Proxima's full profile

Proxima has raised a total funding of $86.3M over 1 round. Its latest funding round was a Seed round on Jan 12, 2026 for $*****. 9 investors participated in its latest round. Proxima has 9 institutional investors.

Here is the list of recent funding rounds of Proxima:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 12, 2026	4274456	Seed	5181642	3932399	7235966	5838909

Access funding benchmarks and valuations. Sign up today!

View details of Proxima's funding rounds and investors

The founders of Proxima is Zachary Carpenter. Zachary Carpenter is the CEO of Proxima.

Here are the details of Proxima's key team members:

Zachary Carpenter: Co-Founder & CEO of Proxima.

View details of Proxima's Founder profiles and Board Members

Proxima's employee count trend

Proxima has 75 employees as of Sep 26. Here is Proxima's employee count trend over the years:

Uncover Proxima's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proxima include Cradle, Generate Biomedicines and Profluent Bio. Here is the list of Top 10 competitors of Proxima, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, Kindred Capital & 7 others	67/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	Pictet Group, NVentures & 14 others	67/100
3rd	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Spark Capital, Altimeter Capital & 6 others	66/100
4th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	64/100
5th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Lux Capital, Amazon & 3 others	64/100
6th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, T. Rowe Price & 23 others	64/100
7th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, RA Capital Management & 11 others	58/100
8th	AI Proteins 2021, Boston (United States), Series A	Developer of de novo designed miniproteins for therapeutic applications	$59.7M	Mission BioCapital, Sante & 4 others	58/100
9th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Lightspeed Venture Partners, Bessemer Venture Partners ... & 12 others	58/100
10th	Converge 2024, Wilmington (United States), Series A	Developer of GenAI computational tools for drug discovery and manufacturing	$30.5M	Bessemer Venture Partners, TLV Partners & 3 others	56/100
18th	Proxima 2019, New York City (United States), Seed	Developer of a platform for programmable protein interaction-based drug discovery	$86.3M	DCVC, NVentures & 7 others	48/100